Nano cap AIM ImmunoTech (NYSEMKT:AIM) jumps 66% premarket on robust volume in reaction to its announcement that
Japan’s National Institute of Infectious Diseases (NIID) will begin
testing Ampligen (rintatolimod), a broad-spectrum antiviral, for the
potential treatment of COVID-19. The testing will be conducted at both
the NIID and University of Tokyo.
https://seekingalpha.com/news/3549664-aim-immunotech-up-66-premarket-on-ampligen-testing-in-japan-for-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.